Lyra Therapeutics stockholders elect three Class II directors and ratify auditor at annual meeting

Lyra Therapeutics, Inc.

Michael Altman, C. Ann Merrifield, and Harlan Waksal elected as Class II directors with votes for 19.7M-19.8M each; 2.5M broker non-votes.
Ratification of BDO USA as independent auditor for FY2022: 22.3M for, 25.5K against, 16.5K abstained.
Approximately 70.19% of outstanding shares (22.3M of ~31.8M) represented at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.